Physician profile
Helen T Shin
NPI 1396799433
$9,179.21
in general payments reported to CMS, 2019-2025
21 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2021: $261 · 2022: $978 · 2023: $1,013 · 2024: $5,059 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Food and Beverage: $3,643 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Food and Beverage | $3,642.59 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,218.95 | 2022-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $1,382.39 | 2024 | Ycanth |
| Amgen INC. | $1,144.84 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $771.43 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $329.39 | 2023-2025 | Zoryve |
| Pierre Fabre Pharmaceuticals, INC. | $285.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $262.52 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $238.72 | 2024-2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.35 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $200.25 | 2019-2025 | Nemluvio |
| Abbvie INC. | $143.81 | 2022 | |
| Pfizer INC. | $143.54 | 2025 | |
| Sanofi-Aventis U.S. LLC | $130.00 | 2021-2024 | |
| Lnhc, INC | $124.98 | 2025 | Zelsuvmi |
| Janssen Biotech, INC. | $122.80 | 2025 | Tremfya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $121.53 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $115.31 | 2023 | Sotyktu |
| Leo Pharma INC. | $107.57 | 2023 | Adbry |
| Lilly USA, LLC | $103.83 | 2024 | |
| Dermavant Sciences, INC. | $14.05 | 2023 | Vtama |
| Organon LLC | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.